A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma

Clinical trial NCT07059299 · RECRUITING

Trial details

NCT number: NCT07059299
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Esophagogastric Junction Adenocarcinoma Gastric Adenocarcinoma Esophageal Adenocarcinoma Resectable Esophagogastric Adenocarcinoma Neoadjuvant Therapy

Start date: 2025-12-12
Primary completion: 2027-08-01
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.